InvestorsHub Logo
icon url

3X Charm

06/08/21 10:25 PM

#169642 RE: misiu143 #169610

Agreed MISIU. Controversial approval to say the least, by FDA on new Alzheimer’s drug. Certainly hypocritical on part of the FDA to parse one trial and not others. Being BIogen certainly helped versus being CYDY certainly hurts. Reputations matter!